Financial Data and Key Metrics Changes - The GAAP net loss for Q1 2020 was $3.6 million or $0.22 per share, compared to a net loss of $3.5 million or $0.24 per share in Q1 2019 [21] - Revenue in Q1 2020 was $62,000, down from $71,000 in Q1 2019, with both periods deriving revenue from integration license agreements [21][24] - The cash balance at March 31, 2020, was $11.4 million, a decline of approximately $3.5 million from $14.9 million at year-end [25] Business Line Data and Key Metrics Changes - The company reported 26 engagements with 19 customers, with 16 engagements in Phase 3, indicating growth in customer pipeline [10] - Non-GAAP research and development expense was $1.8 million in Q1 2020, a decrease from $1.9 million in Q1 2019, attributed to lower outsourced fabrication and testing expenses [22] Market Data and Key Metrics Changes - The semiconductor industry has shown some caution in spending, particularly on CapEx, due to uncertainties related to the coronavirus [10] - The company has seen delays in customer R&D engineering for new programs, impacting the initiation of new R&D lots [11] Company Strategy and Development Direction - The company is focusing on developing deeper and more strategic relationships with customers through joint development agreements (JDAs) [12] - The new 300-millimeter epitaxial deposition tool is expected to enhance R&D capabilities and customer integration runs, allowing for more efficient experimentation [16][19] Management's Comments on Operating Environment and Future Outlook - Management noted that while there have been minor delays due to the coronavirus, business has continued to grow stronger, with increasing customer engagement [28] - The company remains optimistic about the potential of JDAs to accelerate customer adoption of technology [12][28] Other Important Information - The company has cut discretionary spending in response to the economic environment and is closely monitoring hiring and expense increases [27] - The company expects no revenue in Q2 2020 due to delays caused by the coronavirus, but customer work on MST has not ceased [26] Q&A Session Summary Question: Can you discuss the expenses associated with the 300-millimeter tool? - The expenses for the 300-millimeter tool will eventually replace those of the 200-millimeter tool, with timing dependent on acceptance of the new tool [31][32] Question: What does the potential pipeline for JDAs look like? - Discussions on multiple JDAs are ongoing, with some negotiations slowed due to the coronavirus, but management remains hopeful for near-term closures [34][35] Question: What is the minimum cash level the company is comfortable operating with? - The company is closely monitoring cash levels and has no immediate plans to raise additional capital [36] Question: Which technology nodes have the best near-term opportunities for licensing? - RF SOI is seen as having the best near-term opportunity for production ramp-up, while power management also presents a lucrative market [40] Question: Is the new 300-millimeter tool expected to provide cash burn benefits? - The new tool will lead to more predictable expenses and increased productivity, although it will be at a slightly higher cost than previous outsourced runs [46]

Financial Performance - Revenue for the year ended December 31, 2019 was approximately $533,000, an increase from $246,000 in 2018, representing a growth of 116.3%[120] - Cost of revenue for 2019 was approximately $253,000, up from $148,000 in 2018, indicating a rise of 70.3%[121] - Operating expenses totaled approximately $13.9 million for 2019, compared to $13.2 million in 2018, reflecting an increase of 5.3%[122] - The net loss for the year ended December 31, 2019 was approximately $13.3 million, compared to a net loss of approximately $12.9 million in 2018[131] Expenses Breakdown - Research and development expenses for 2019 were approximately $7.7 million, an increase of 6% from $7.3 million in 2018[124] - General and administrative expenses rose to approximately $5.2 million in 2019, up 5% from $5.0 million in 2018[125] Cash Position - As of December 31, 2019, cash and cash equivalents were approximately $14.9 million, with working capital of approximately $13.5 million[131] - Net cash used in operating activities for 2019 was approximately $10.4 million, primarily due to the net loss adjusted for stock-based compensation[134] Future Outlook - The company anticipates increased fees from license agreements and royalties as it enters into manufacturing and distribution license agreements[118] - Future capital requirements will depend on the successful commercialization of technology and potential collaborations or acquisitions[133]

Financial Data and Key Metrics Changes - The company reported a GAAP net loss of $13.3 million for the year ended December 31, 2019, compared to a net loss of $12.9 million in 2018, primarily due to higher operating expenses [19] - Revenue for 2019 was $533,000, an increase from $246,000 in 2018, with $259,000 from license agreements and $274,000 from engineering services [19][20] - The GAAP net loss for Q4 2019 was $3 million, an improvement from a loss of $3.2 million in Q4 2018, attributed to lower operating expenses [22] Business Line Data and Key Metrics Changes - In Q4 2019, revenue consisted of $113,000 from a license agreement and $25,000 from engineering services, compared to $150,000 in Q4 2018 [22] - The company delivered more than three times the amount of MST wafers to customers in late 2019, indicating a record level of customer engagement [9][10] Market Data and Key Metrics Changes - The company is focusing on three key areas: RF SOI for 5G devices, BCD for advanced power chips, and next-generation devices, with a significant increase in customer integration runs [10][12] - The company is working with customers whose RF SOI manufacturing capacity represents more than half of the entire installed base in the industry [16] Company Strategy and Development Direction - Atomera is evolving its contract structures to accommodate longer engagement periods and deeper relationships with customers, moving towards joint development agreements [12][13] - The company aims to leverage its technology across multiple production lines and processes, enhancing customer penetration and adoption [13] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's positioning for growth in 2020, citing increased customer engagement and a record number of MST wafers delivered [27] - The company anticipates a cash use of approximately $13 million to $13.5 million for 2020, reflecting an increase due to planned headcount additions and delayed tool lease expenses [24][25] Other Important Information - The company reported a cash balance of $14.9 million at the end of 2019, a decline from $18.9 million at the end of 2018 [23] - The company is experiencing a bottleneck in personnel, which is impacting its ability to engage with new customers [45] Q&A Session Summary Question: Discussion on the EPI tool and its opportunities - Management confirmed that the EPI tool installation was delayed but is expected to enhance both internal R&D and customer deposition capabilities once operational [30] Question: Joint development agreements and customer eligibility - Joint development agreements are being discussed with multiple customers, primarily larger and newer ones, to prequalify Atomera's technology across multiple product lines [32][34] Question: Prioritization of resources across technology areas - The company is prioritizing customers based on their likelihood to reach production sooner, with RF SOI and BCD being the primary focus areas due to a larger customer base [36] Question: Impact of new technologies on customer engagement - There is a pent-up demand from customers interested in working with Atomera, but the company has been too busy to fully engage with them [43] Question: Cash use expectations for 2020 - The expected cash use for 2020 is in the range of $13 million to $13.5 million, reflecting increased operational expenses and headcount [46] Question: Phase 3 engagements and transition to Phase 4 - Some customers in Phase 3 are close to completing their work, but delays may occur due to external factors unrelated to Atomera's technology [51][56] Question: Impact of the coronavirus on customer engagement - The company is adapting to virtual meetings due to travel restrictions but does not foresee significant long-term impacts on existing customer relationships [60]

Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock: Par value $0.001 ATOM Nasdaq Capital Market Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly Report Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2019. or ¨ Transition Report Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the transition period from ______ ...

Atomera, Inc. (NASDAQ:ATOM) Q3 2019 Earnings Conference Call October 30, 2019 5:17 PM ET Company Participants Mike Bishop - Investor Relations Francis Laurencio - Chief Financial Officer Scott Bibaud - President and Chief Executive Officer Conference Call Participants Cody Acree - Drexel Hamilton Sujeeva Desilva - Roth Capital Partners Operator Ladies and gentlemen, thank you for standing by and welcome to the Atomera Third Quarter 2019 Financial Results Conference Call. [Operator Instructions] I would now ...

Atomera, Inc. (NASDAQ:ATOM) Q2 2019 Results Conference Call August 7, 2019 5:00 PM ET Company Participants Mike Bishop - IR Scott Bibaud - President and CEO Frank Laurencio - CFO Conference Call Participants Operator Good afternoon and welcome to the Atomera Second Quarter 2019 Earnings Call. All participants will be in listen-only mode. [Operator Instructions] After today's presentation, there will be an opportunity to ask questions. [Operator Instructions] This event is being recorded and will be availabl ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly Report Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2019. or ¨ Transition Report Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the transition period from __________ to __________ Commission file number: 001-37850 ATOMERA INCORPORATED (Exact name of registrant as specified in its charter) Delaware (Stat ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly Report Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2019. or ¨ Transition Report Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the transition period from __________ to __________ Commission file number: 001-37850 ATOMERA INCORPORATED (Exact name of registrant as specified in its charter) | --- | |---- ...